

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 4<sup>th</sup> July, 2018

**ORDER**

S. O. 3242(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (8) thereof;

**Table**

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Retail Price (Rs.)	Review Order number and date	Existing SO number & date	Manufacturer & Marketing Company respectively
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
1.	Atorvastatin + Clopidogrel Capsule (Atocor CV 10)	Each hard gelatin capsule contains: Atorvastatin 10mg Clopidogrel 75mg	1 Capsule	10.92	31015/09/2018- Pricing dated 29.05.2018	3915(E) dated 18.12.2017 (at Sl. No. 50)	M/s Windlas Biotech Pvt. Ltd. / M/s Dr. Reddy's Laboratories Ltd.
2.	Atorvastatin + Clopidogrel Capsule (Atocor CV 20)	Each hard gelatin capsule contains: Atorvastatin 20mg Clopidogrel 75mg	1 Capsule	15.625	31015/09/2018- Pricing dated 29.05.2018	02(E) dated 01.01.2018 (at Sl. No. 10)	M/s Windlas Biotech Pvt. Ltd. / M/s Dr. Reddy's Laboratories Ltd.
3.	Telmisartan + Chlorthalidone Tablet (Tigatel CH 80)	Each film coated tablet contains: Telmisartan IP 80mg Chlorthalidone IP 12.5mg	1 Tablet	13.06	31015/13/2018- Pricing dated 29.05.2018	02(E) dated 01.01.2018 (at Sl. No. 04)	M/s Sun Pharma Laboratories Limited
4.	Cefixime + Ofloxacin Tablet (Ranixime Plus)	Each film coated tablet contains: Cefixime Trihydrate eq. to Cefixime anhydrous IP 200mg, Ofloxacin IP 200mg	1 Tablet	10.59	31015/6/2018- Pricing dated 29.05.2018	3915(E) dated 18.12.2017 (at Sl. No. 40)	M/s Theon Pharmaceuticals Limited / M/s Sun Pharmaceutical Industrial Limited
5.	Rosuvastatin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg, Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Capsule	16.60	31015/12/2018- Pricing dated 08.06.2018	02(E) dated 01.01.2018 (at Sl. No. 14)	M/s Synokem Pharmaceuticals Ltd. / M/s Eris Lifesciences Limited
6.	Rosuvastatin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets)	1 Capsule	16.06	31015/14/2018- Pricing dated 29.5.2018	02(E) dated 01.01.2018 (at Sl. No. 5)	M/s. Synokem Pharmaceuticals Ltd. / M/s Zydus Healthcare Ltd.

Note:

- (a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
- (f) The concerned manufacturer of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturer, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

PN/190/58/2017/F

F. No. 8(58)/2018/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director